Search results for "Randomized Controlled Trials as Topic"

showing 10 items of 435 documents

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for mul…

2016

Abstract Background Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. Methods Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance. We summarized results using a best-…

Malelaw.inventionpsychosis.0302 clinical medicinePiperidinesRandomized controlled triallawDonepezilDonepezilRandomized Controlled Trials as Topicbipolar disorderClinical Trials as TopicEvidence-Based MedicineDepressionMemantineMiddle AgedManiaPsychiatry and Mental healthClinical PsychologyTreatment Outcomeacetylcholinesterase inhibitorsdepressionIndansFemalemedicine.symptomPsychologyManiamedicine.drugAdultmedicine.medical_specialtyBipolar disorderPlaceboBipolar disorder Acetylcholinesterase inhibitors Memantine Depression Mania Psychosis03 medical and health sciencesmaniaMemantineInternal medicinemedicineGalantamineHumansBipolar disorderAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis.PsychiatryDepressive DisorderGalantaminePsychosismedicine.disease030227 psychiatryAcetylcholinesterase inhibitorsMoodPsychotic DisordersAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis; Psychiatry and Mental Health; Clinical PsychologyCase-Control StudiesmemantineCholinesterase InhibitorsExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies

2019

[Background]: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. [Methods]: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemTime FactorsMediterranean dietEndocrinology Diabetes and MetabolismhumanosDiseaseType 2 diabetes030204 cardiovascular system & hematologyDiet Mediterraneanchemistry.chemical_compound0302 clinical medicineRisk Factorsestudios prospectivosevaluación de riesgosMetabolites030212 general & internal medicineProspective Studiesmediana edadOriginal InvestigationPipecolic acidRandomized Controlled Trials as TopicAged 80 and overancianodietaácidos pipecólicosensayos clínicos controlados aleatorizados como asuntoresultado del tratamientoIncidenceType 2 diabetesMiddle AgedCardiovascular disease3. Good healthPrimary PreventionTreatment OutcomeCardiovascular DiseasesPipecolic AcidsFemaleCardiology and Cardiovascular Medicineconducta de reducción del riesgoCohort studymedicine.medical_specialtyenfermedades cardiovascularesácido 2-aminoadípicoRisk Assessmentincidencia03 medical and health sciencesfactores de tiempoInternal medicineDiabetes mellitusmedicineDiabetes Mellitusfactores de riesgoHumansAngiologyAgedProportional hazards modelbusiness.industryLysinemedicine.diseaseDietlisinaDietary interventionchemistryDiabetes Mellitus Type 2lcsh:RC666-701business2-Aminoadipic AcidRisk Reduction BehaviorBiomarkers
researchProduct

Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study

2015

International audience; BACKGROUND: Fractional flow reserve (FFR) measured by coronary computed tomography angiography (FFRCT) has been validated against invasive FFR. However, there are no data on how the use of FFRCT affects patient care and outcomes. The aim of this study is to compare standard practice guided by usual care testing to FFRCT-guided management in symptomatic subjects with suspected coronary artery disease (CAD). METHODS: In this prospective nonrandomized trial, symptomatic patients with suspected CAD will be enrolled in 2 consecutive cohorts: a usual care-guided pathway (cohort 1) and an FFRCT-guided pathway (cohort 2). Each cohort is divided into 2 groups according to whe…

Malemedicine.medical_specialty*Tomography[SDV]Life Sciences [q-bio]Fractional flow reserveCoronary Artery DiseaseCoronary AngiographyCoronary Angiography/*methodsCoronary artery diseaseCoronary Artery Disease/*diagnosis/physiopathologyQuality of lifeRandomized Controlled Trials as Topic/*methodsPredictive Value of TestsMyocardial/*physiologyOutcome Assessment Health CareClinical endpointMedicineHumansProspective StudiesProspective cohort studyRandomized Controlled Trials as TopicAgedbusiness.industryMiddle Agedmedicine.diseaseFractional Flow Reserve3. Good healthX-Ray ComputedFractional Flow Reserve MyocardialStenosisPredictive value of testsCohortFemaleRadiologyOutcome Assessment (Health Care)/*methodsCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct

Non‐Pharmacologic Multicomponent Interventions Preventing Delirium in Hospitalized People

2020

BACKGROUND/OBJECTIVES Delirium is a common neurobehavioral complication in hospitalized patients with a high prevalence in various clinical settings. Prevention of delirium is critical due to its common occurrence and associated poor outcomes. Our objective was to evaluate the efficacy of multicomponent interventions in preventing incident delirium in hospitalized patients at risk. DESIGN Systematic review and meta-analysis. SETTING Hospital. PARTICIPANTS We included a study if it was a randomized controlled trial and was evaluating effects of coordinated non-pharmacologic multicomponent interventions in the prevention of delirium. MEASUREMENTS We performed a systematic literature search in…

Malemedicine.medical_specialty610 Medizinmulticomponent interventions ; delirium ; prevention ; non-pharmacologic interventionslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallaw610 Medical sciencesOutcome Assessment Health Caremental disordersmedicineHumans030212 general & internal medicineAgedRandomized Controlled Trials as TopicAged 80 and overInpatientsInpatient mortalitybusiness.industryIncidenceIncidence (epidemiology)Multicomponent interventionsDeliriumMiddle AgedAccidentalEmergency medicineDeliriumFemalePreventive MedicineGeriatrics and Gerontologymedicine.symptomComplicationbusiness030217 neurology & neurosurgeryIndependent livingJournal of the American Geriatrics Society
researchProduct

Causes of ineligibility in randomized controlled trials and long-term mortality in patients with non-ST-segment elevation acute coronary syndromes

2006

To determine the long-term mortality of patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) that are eligible versus those not eligible in randomized controlled trials (RCT), and how each exclusion criteria is associated with outcome.Common causes of exclusion in six published RCT on intravenous antithrombotic therapy were prospectively assessed in a cohort of 452 consecutive patients with NSTEACS that were followed for up to 3 years.Forty-one percent of patients had one or more exclusion criteria establishing the ineligible group. These patients were older, more likely to have coronary risk factors, ischemic ECG changes, heart failure at admission, higher creatinine l…

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentRevascularizationlaw.inventionElectrocardiographyRandomized controlled trialRisk FactorslawInternal medicinemedicineHumansThrombolytic TherapyProspective StudiesAcute Coronary SyndromeProportional Hazards ModelsRandomized Controlled Trials as TopicEjection fractionbusiness.industryPatient SelectionMortality rateST elevationmedicine.diseaseSurgeryClinical trialTreatment OutcomeEchocardiographyCohortFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials

1997

Summary Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Many treatments have been proposed but considerable uncertainty still remains about their effectiveness. In this review we evaluated the quality, clinical coherence, consistency and results of Randomized Controlled Trials (RCT) of non-surgical treatments for HCC. Methods Thirty-seven RCTs examining the effect of different treatments were retrieved using MEDLINE (November 1978 to December 1995) and a review of reference lists. Selected aspects of the quality of design, conduct and reporting were examined. The odds ratio for the probability of surviving up to one year was calculated according to the …

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentlaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansEmbolizationRandomized Controlled Trials as Topicbusiness.industryArterial EmbolizationLiver NeoplasmsHematologyOdds ratioEmbolization TherapeuticChemotherapy regimenSurgeryClinical trialClinical Trials Phase III as TopicOncologyMeta-analysisImmunotherapybusinessAnnals of Oncology
researchProduct

Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis o…

2015

Introduction: Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. Methods:The searchincludedPUBMED,Cochrane Library,Web ofScience,Scopus,andEMBASE(up toAugust31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weig…

Malemedicine.medical_specialtyCardiotonic AgentsResveratrolCochrane LibraryRisk AssessmentSeverity of Illness IndexGastroenterologyAntioxidantslaw.inventionToxicologychemistry.chemical_compoundRandomized controlled triallawInternal medicineStilbenesHumansMedicineRandomized Controlled Trials as Topicbiologybusiness.industryCholesterolC-reactive proteinPrognosisConfidence intervalSurvival RateC-Reactive ProteinTreatment OutcomeBlood pressurechemistryCardiovascular DiseasesResveratrolMeta-analysisbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Is Overall Mortality the Right Composite Endpoint in Clinical Trials of Acute Respiratory Distress Syndrome?

2018

Objectives Overall mortality in patients with acute respiratory distress syndrome is a composite endpoint because it includes death from multiple causes. In most acute respiratory distress syndrome trials, it is unknown whether reported deaths are due to acute respiratory distress syndrome or the underlying disease, unrelated to the specific intervention tested. We investigated the causes of death after contracting acute respiratory distress syndrome in a large cohort. Design A secondary analysis from three prospective, multicenter, observational studies. Setting A network of multidisciplinary ICUs. Patients We studied 778 patients with moderate-to-severe acute respiratory distress syndrome…

Malemedicine.medical_specialtyCritical Care and Intensive Care MedicineHypoxemia03 medical and health sciences0302 clinical medicineInternal medicineCause of DeathmedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyCause of deathRandomized Controlled Trials as TopicRespiratory Distress SyndromeLungbusiness.industryMiddle AgedClinical trialmedicine.anatomical_structure030228 respiratory systemRelative riskCohortBreathingmedicine.symptombusinessCritical care medicine
researchProduct

Epidemiology, prevention and screening for prostate cancer.

1996

Prostate cancer is a growing social problem. The economical impact is high and is likely to become greater in future years, not only because the number of patients diagnosed with prostatic neoplasias is increasing steadily, but also because of the promotion of screening programmes and the rise in the number of surgical procedures available. It can be concluded that, at the present stage, widespread implementation of screening cannot be recommended. The answer to the question of screening can only be provided by large randomised trials, comparing either screening versus no screening, or early versus delayed treatment in patients in whom early cancer is detected by screening.

Malemedicine.medical_specialtyEarly cancerUrologyCost-Benefit AnalysisRisk AssessmentProstate cancerEpidemiologymedicineHumansMass ScreeningIn patientStage (cooking)Intensive care medicineRandomized Controlled Trials as TopicPalpationbusiness.industryRectumProstatic NeoplasmsDelayed treatmentSurgical proceduresMiddle AgedProstate-Specific Antigenmedicine.diseasePrimary PreventionPhysical therapybusinessEuropean urology
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct